GPX3, glutathione peroxidase 3, 2878

N. diseases: 156; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident 		0.020 Biomarker group BEFREE 1996;97:979-987), plasma from 2 brothers with stroke or transient ischemic attack inactivated the antiplatelet effects of nitric oxide (NO), and this effect was found to be a consequence of a deficiency of plasma glutathione peroxidase (GSH-Px). 10446087 1999
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.010 Biomarker disease BEFREE 1996;97:979-987), plasma from 2 brothers with stroke or transient ischemic attack inactivated the antiplatelet effects of nitric oxide (NO), and this effect was found to be a consequence of a deficiency of plasma glutathione peroxidase (GSH-Px). 10446087 1999
CUI: C0917805
Disease: Transient Cerebral Ischemia
Transient Cerebral Ischemia 		0.010 Biomarker disease BEFREE 1996;97:979-987), plasma from 2 brothers with stroke or transient ischemic attack inactivated the antiplatelet effects of nitric oxide (NO), and this effect was found to be a consequence of a deficiency of plasma glutathione peroxidase (GSH-Px). 10446087 1999
CUI: C0004763
Disease: Barrett Esophagus
Barrett Esophagus 		0.030 AlteredExpression disease LHGDN GPx3 promoter hypermethylation was detected in 62% of Barrett's metaplasia, 82% of dysplasia, and 88% of BA samples. 16229808 2005
CUI: C0004763
Disease: Barrett Esophagus
Barrett Esophagus 		0.030 PosttranslationalModification disease BEFREE GPx3 promoter hypermethylation was detected in 62% of Barrett's metaplasia, 82% of dysplasia, and 88% of BA samples. 16229808 2005
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm 		0.020 AlteredExpression disease LHGDN GPx3 mRNA was exclusively localized to the thyrocytes, showed the highest expression levels and was down-regulated in 5 of 6 thyroid cancer samples as compared to matched normal controls. 17937619 2007
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE Glutathione peroxidase 3 (GPX3) can enhance an antioxidant's capacity and reduce genomic damage caused by oxidants and thus influence tumorigenesis. 20576521 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.360 AlteredExpression disease BEFREE GPx3, a gene identified by this analysis, was found to be down-regulated by high fat diet and appears be decreased in human prostate cancers, suggesting that GPx3 may have a possible role in modulating carcinogenesis.Prostate 71:1499-1509, 2011.© 2011 Wiley-Liss, Inc. 21374652 2011
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 Biomarker phenotype BEFREE GPx3, a gene identified by this analysis, was found to be down-regulated by high fat diet and appears be decreased in human prostate cancers, suggesting that GPx3 may have a possible role in modulating carcinogenesis.Prostate 71:1499-1509, 2011.© 2011 Wiley-Liss, Inc. 21374652 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.080 PosttranslationalModification group BEFREE GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. 21684681 2011
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.100 PosttranslationalModification phenotype BEFREE GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. 21684681 2011
CUI: C0278996
Disease: Malignant Head and Neck Neoplasm
Malignant Head and Neck Neoplasm 		0.010 PosttranslationalModification disease BEFREE GPx3 methylation may have implications in chemotherapy response and clinical outcome of HNC patients. 21684681 2011
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma 		0.010 PosttranslationalModification disease BEFREE GPx3 methylation may have implications in chemotherapy response and clinical outcome of HNC patients. 21684681 2011
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.030 AlteredExpression group BEFREE GPX3 mRNA levels were significantly higher in primary carcinomas and solid metastases from patients who received neoadjuvant chemotherapy compared with chemo-naïve tumors (P = .016). 24926085 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.070 AlteredExpression phenotype BEFREE GPX3 mRNA levels were significantly higher in primary carcinomas and solid metastases from patients who received neoadjuvant chemotherapy compared with chemo-naïve tumors (P = .016). 24926085 2014
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.030 AlteredExpression group BEFREE GPX3 mRNA levels were significantly higher in primary carcinomas and solid metastases from patients who received neoadjuvant chemotherapy compared with chemo-naïve tumors (P = .016). 24926085 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 Biomarker group BEFREE GPx3 could be delivered by hiPSC-MSCs into the tumor and exhibited tumor suppressive activity in vivo. 25333265 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 PosttranslationalModification group BEFREE GPX3 promoter methylation was detected in 46 of 60 (76.7%) tumors, while no GPX3 gene promoter methylation was observed in the matched non-cancerous specimens. 25445749 2015
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.360 Biomarker disease BEFREE GPX3 gene is located in 5q23, which is frequently deleted in prostate cancer. 25929866 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.060 Biomarker disease BEFREE GPX3 gene is located in 5q23, which is frequently deleted in prostate cancer. 25929866 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 PosttranslationalModification group BEFREE GPX3 was methylated in 46.8% (44 of 94) of PTC and methylation of GPX3 was associated with tumor size (P<0.05) and regional lymph node metastasis (P<0.01) significantly. 25929866 2015
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.060 PosttranslationalModification disease BEFREE GPX3 was methylated in 46.8% (44 of 94) of PTC and methylation of GPX3 was associated with tumor size (P<0.05) and regional lymph node metastasis (P<0.01) significantly. 25929866 2015
CUI: C0023418
Disease: leukemia
leukemia 		0.020 PosttranslationalModification disease BEFREE GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. 27891827 2017
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.020 PosttranslationalModification disease BEFREE GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. 27891827 2017
CUI: C2347761
Disease: Childhood Myelodysplastic Syndrome
Childhood Myelodysplastic Syndrome 		0.010 PosttranslationalModification disease BEFREE GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. 27891827 2017